Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Enhancing the anti-tumour activity of 177Lu-DOTA-octreotate radionuclide therapy in somatostatin receptor-2 expressing tumour models by targeting PARP

23 Jun 2020

Abstract excerpt

Abstract Peptide receptor radionuclide therapy (PRRT) is an important treatment option for patients with somatostatin receptor-2 (SSTR2)-expressing neuroendocrine tumour (NET) though tumour regression occurs in only a minority of patients. Therefore, novel PRRT regimens with improved therapeutic activity are needed. Radiation induced DNA damage repair is an attractive therapeutic target to increase PRRT efficacy...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Lung Cancer Research Studies
Share to Neuroblastoma Research and Treatments
Share to Neuroendocrine Tumor Research Advances

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Source

Identifiers

PMID: 32576907
DOI: 10.1038/s41598-020-67199-9

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 8 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Enhancing the anti-tumour activity of 177Lu-DOTA-octreotate radionuclide therapy in somatostatin receptor-2 expressing tumour models by targeting PARPPMID 32576907Read ↗

Understanding the Radiobiological Mechanisms Induced by 177Lu-DOTATATE in Comparison to External Beam Radiation TherapySemantic proximity Read ↗

DNA-PKcs inhibitors sensitize neuroendocrine tumor cells to peptide receptor radionuclide therapy in vitro and in vivoSemantic proximity Read ↗

A pan-cancer analysis of the clinical and genetic portraits of somatostatin receptor expressing-tumor as a potential target of peptide receptor imaging and therapySemantic proximity Read ↗

Discovery of an SSTR2-Targeting Maytansinoid Conjugate (PEN-221) with Potent Activity in Vitro and in VivoSemantic proximity Read ↗

Radiosensitization of NET cells by HSP90 inhibitor ganetespib is mediated through pleiotropic stress responsesSemantic proximity Read ↗

A genome-wide CRISPR/Cas9 screen identifies DNA-PK as a sensitiser to 177 Lutetium-DOTA-octreotate radionuclide therapySemantic proximity Read ↗

Epigenetic potentiation of somatostatin-2 by guadecitabine in neuroendocrine neoplasias as a novel method to allow delivery of peptide receptor radiotherapySemantic proximity Read ↗

Upregulation of Somatostatin Receptor Type 2 in a Receptor-Deficient <i>In Vivo</i> Pancreatic Neuroendocrine Tumor Model Improves Tumor Response to Targeted <sup>177</sup> Lu-DOTATATESemantic proximity Read ↗

An evaluation in vitro of PARP-1 inhibitors, rucaparib and olaparib, as radiosensitisers for the treatment of neuroblastomaSemantic proximity Read ↗

Somatostatin Receptor Based Imaging and Radionuclide TherapySemantic proximity Read ↗

Limitations of the radiotheranostic concept in neuroendocrine tumors due to lineage-dependent somatostatin receptor expression on hematopoietic stem and progenitor cellsSemantic proximity Read ↗

Theranostics for Neuroblastoma: Making Molecular Radiotherapy Work BetterSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.